• Home
  • About Us
    • About us
    • Scientific Advisory Board
    • People
    • Business Strategy
    • Event Calendar
  • Development
    • Portfolio
    • APTA-1
    • Intellectual property and patent
    • What is sepsis?
  • Market
    • Sepsis
    • Clinical application
  • Investor Relations
    • Company Information
    • Financial Information
    • Largest Shareholders
    • Financial Calendar
    • Presentations
  • News
    • World Sepsis Day
  • Contact
  • en
  • Home
  • About Us
    • About us
    • Scientific Advisory Board
    • People
    • Business Strategy
    • Event Calendar
  • Development
    • Portfolio
    • APTA-1
    • Intellectual property and patent
    • What is sepsis?
  • Market
    • Sepsis
    • Clinical application
  • Investor Relations
    • Company Information
    • Financial Information
    • Largest Shareholders
    • Financial Calendar
    • Presentations
  • News
    • World Sepsis Day
  • Contact
  • en

News

Home / News /
  0
By Erika Medin
In News
Posted 23 June 2022

Aptahem confirms that lead candidate Apta-1 shows very good tolerability in the GLP tox studies

Aptahem AB (publ) announces today that the final study report from the GLP (Good Laboratory Practice) toxicology and safety studies has been finalized. The report confirms the previously [...]

READ MORE
  0
By Erika Medin
In News
Posted 20 June 2022

BioStock article: Aptahem’s new CMO on her role and vision

BioStock published an article on 17 June 2022 about Aptahem, which can be read in full below. Aptahem has appointed Dr Ingela Hallberg as the new Medical Director. The company is thus putting [...]

READ MORE
  0
By Erika Medin
In News
Posted 1 June 2022

Aptahem appoints Ingela Hallberg as new CMO

Aptahem (publ) announces today that Ingela Hallberg has been appointed new Chief Medical Officer (CMO) in the company as of 1 June 2022. Ingela has long and solid experience from the [...]

READ MORE
  0
By Erika Medin
In News
Posted 23 May 2022

BioStock article: Aptahem signs agreement with CRO for phase I studies

BioStock published an article on 23 May 2022 about Aptahem, which can be read in full below. Aptahem has entered into an agreement with a clinical contract research organisation in the [...]

READ MORE
  0
By Erika Medin
In News
Posted 17 May 2022

Aptahem enters agreement with international clinical CRO for phase 1 studies with Apta-1

Aptahem (publ) announces today that the company has signed an agreement with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to [...]

READ MORE
  0
By Erika Medin
In News
Posted 9 May 2022

Aptahem enters new consortium financed by the KK Foundation

Aptahem (publ) today announce that the company enters a consortium together with Örebro University, Attgeno AB, BioReperia AB, Buzzard Pharmaceuticals AB, Lipum AB, Thermo Fisher Scientific och [...]

READ MORE
  0
By Erika Medin
In News
Posted 9 March 2022

BioStock article: Aptahem on the latest news

BioStock published an article on 9 March 2022 about Aptahem, which can be read in full below. Aptahem has communicated several positive news lately. Recently, the company received patent [...]

READ MORE
  0
By Erika Medin
In News
Posted 7 March 2022

Aptahem reports prepared GMP certified Apta-1 for preparation of clinical studies

Aptahem announces today that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 successfully has been prepared by the collaboration partner LGC [...]

READ MORE
  0
By Erika Medin
In News
Posted 21 February 2022

Aptahem reports additional positive biological effect in a Corona virus-induced acute lung injury model treated with Apta-1

Aptahem can today announce that in addition to previously reported positive preliminary data, the Toronto team has, from further studies, found essential positive effects in a Corona virus [...]

READ MORE
  0
By Erika Medin
In News
Posted 16 February 2022

Aptahem receives patent protection in Japan for patent family 2

Aptahem AB (publ) announces today that the company has received patent protection in Japan for patent family 2 from the Japanese Patent Office (JPO). With JPO’s approval of patent application [...]

READ MORE
1 2 3 4 5 6 7 8 9 10
page 1 of 10
Contact



Norra Vallgatan 58, 4 TR
211 22 Malmö
Sweden
E-mail: info@aptahem.com

Aptahem is supporting Global Sepsis Alliance
To all salesmen:

We kindly decline all direct contact with salesmen of different types of products and services.

Copyright All Rights Reserved © 2016

Start typing and press Enter to search